Adaptive Medicine 11(3): |
75 |
DOI: 10.4247/AM.2019.ABJ230 |
|
Review Article
Great Achievements and New Landscapes in Medical Cancer Therapy
Daniel Gandia1 and Cecilia Suárez 2
1M.D. Cancer Medicine, Buenos Aires, Argentina
2PhD, Complex Systems Lab, INFIP, FCEyN,
Chemotherapy rapidly proved its worth in different clinical cancer settings, begining with hematologic ma- lignancies. Many pediatric and young adult tumors achieved complete remission with chemotherapy, but its use as concomitant, adjuvant and/or neoadjuvant treatment also resulted in beneficial results. The new milenium developed new techniques in molecular drug design creating novel drugs specially directed to spe- cific cell targets, which was a solution for some tradi- tionally chemoresistant tumors. César Milstein begun a new road with the discovery of the monoclonal anti- bodies, opening the landscape of the
Key words: cancer, chemotherapy, drug design, immuno- oncology, “omics” sciences, mathematical on- cology, metronomics, personalized medicine
Medical Cancer Treatment has evolved in an ex- ponential manner since Gilman and Goodman´s mechlorethamine introduction into the bedside (10).
Since then, chemotherapy rapidly proved its worth in different clinical cancer settings. Initial eye- opener results were seen in hematologic malignan- cies, namely complete remissions in some types of leukemias
The new milenium developed new techniques in molecular drug design creating novel drugs (named small molecules) specially directed to specific cell targets (mainly tyrosine kinases and mutated DNA segments). This approach was a solution for some
Corresponding authors: Daniel Gandia, Department of Cancer Medicine, UBA. Mobile: +54 9116 4965444, T.E.: +544 11 45284 3533, E-
mail: daniel.gandia@iqvia.com
Received: July 30, 2019; Revised: August 24, 2019; Accepted: August 26, 2019.
2019 by The Society of Adaptive Science in Taiwan. ISSN :
76 |
Gandía and Suárez |
traditionally chemoresistant tumors such us renal clear cell cancer, melanoma and lung cancer (sunit-
Cancer is an extremely complex disease that in- volves the different levels of biological organization (16). On the last decades mathematical and compu- tational oncology came to help with this complexity, with the final aim of working as a complementary clinical tool. The
Multiscale ABM models allow the simulation of the behavior of different cell populations (meso- scopic level) as well as the inner physiology of indi- vidual cells (microscopic level) (37). This approach lets the analysis of phenotipic mutations, effects of oxygen and nutrient availability, adaptation to microenvironment, neoangiogenesis, and therapy respones, among other phenomena. On the other hand, relatively simple (mathematically speaking)
*Nobel Prize in Physiology or Medicine 2018; Nature Collection, 1 October 2018
continuum models, made at the macroscopic tissue level and based on
With the development of the bioinformatics, data mining and machine learning, the possibility of managing and extracting valuable information from a great quantity of biological/medical data derived from new molecular and imaging technologies be- came feasible (8). This lead to the appearance of the “omics” sciences, as genomics, proteomics, radiom- ics, radiogenomics, etc. Among them, radiomics and radiogenomics are the newer ones and are being intensively explored nowadays. The term “radiomics” was introduced in 2012 in the context of the medical imaging analysis. Medical radiomics is the compu- tational image analysis able to extract a great num- ber of quantitative characteristics from a particular image that cannot be obtained by the naked operator eye (21, 28). Indeed, the possibility of introducing information derived from these “omics” sciences into hybrid and/or multiscalar mathematical models are nowadays the approaches most interesting and promising with good perspectives in the diagnosis, prognosis, treatment design and
Traditionally, cancer was treated mainly as
a
Although at present many tumor types can be completely cured, other ones are much more difficult to eradicate, and they would be better considered as chronic diseases. This led to the appearance of an
Main Cancer Treatment Abordances |
77 |
adaptive therapeutic approach that must evolve in response to the temporal and spatial variability of the tumor (metronomic therapy (15). In this context, some critical factors must be taken into more account. First, to keep a stable tumor burden (lesser tumor shrinkage means lesser tissue toxicity). Second, to design treatment strategies aimed to keep the tumor quiet avoiding its progression into more aggressive grades (letting more benign chemosensitive cell populations to survive and win the competence with more aggresive chemoresistant ones). Third, with a longer disease hold, quality of life issues emerges as much more important
Conflict of Interest
No relationships.
References
1.Abdallah M, Blonski M,
2.Abigerges D., Armand J., Chabot G., Da Costa L., Fadel E., Cote C., Herait P. and Gandia D. Irinotecan
3.Abigerges D., Chabot G., Armand J., Herait P., Gouyette A and Gandia D. Phase I and pharmacologic studies of the campthotecin analog Irinotecan administered every 3 weeks in cancer patients. J. Clin Oncol. 13:
4.Alameddine A., Conlin F. and Binnall B. An introduction to the mathematical modeling in the study of cancer systems biology. Cancer Inf. 17: 1176935118799754, 2018.
5.Bonadonna G., Brusamolino E., Valagussa P., Rossi A., Brugnatelli L., Brambilla C., De Lena M., Tancini G., Bajetta E., Musumeci R. and Veronesi U. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N. Eng. J. Med. 294:
6.Bonadonna G., Moliterni A., Zambetti M., Daidone M., Pilotti S., Gianni L. and Valagussa P. 30 years’
7.Bonadonna G., Valagussa P., Moliterni A., Zambetti M. and Bram- billa C. Adjuvant cyclophosphamide, methotrexate and fluorou- racil in
8.Chakraborty S., Hosen I., Ahmed M. and Shekhar H.
9.Chamseddine M. and Rejniak K. Hybrid modeling frameworks of tumor development and treatment. Willey Inter Rev Syst Biol.
Med. e1461, 2019.
10.Christakis P. The birth of chemotherapy at Yale; Bicentennial lec- ture series: Surgery grand round. Yale J. Biol. Med. 84:
11.Cvitkovic E., Spaulding J., Bethune V., Martin J. and Whitmore W. Inprovement of
12.David U., Beroukhim R. and Golub T. Genomic evolution of can- cer models: Perils and opportunities. Nat. Rev. Cancer 19:
13.Department of Veterans Affairs Laryngeal Cancer Study Group; Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N. Eng. J. Med. 324:
14.Gandia D., Abigerges D., Armand J., Chabot G., Da Costa L., De Forni M.,
15.Gatenby R., Silva A., Gillies R. and Frieden B. Adaptive therapy. Cancer Res. 69:
16.Hanahan D. and Weinberg R; Hallmarks of Cancer. The next gen- eration. Cell 144:
17.Hayes D., Cvitkovic E., Golbey R., Scheiner E., Helson L. and Krakoff I. High dose
18.Jackson P., Juliano J.,
19.Kohler G. and Milstein C. Continuous cultures of fused cells se- creting antibody of predefined specificity. Nature 256:
20.Korolev K., Xavier J. and Gore J. Turning ecology and evolution against cancer. Nat. Rev. Cancer 5:
21.Lambin, P., Leijenaar, R.T.H., Deist, T.M., Peerlings, J., de Jong, E.E.C., van Timmeren, J., Sanduleanu, S., Larue, R.T.H.M., Even, A.J.G., Jochems, A., van Wijk, Y., Woodruff, H., van Soest, J., Lustberg, T., Roelofs, E., van Elmpt, W., Dekker, A., Mottaghy, F.M., Wildberger, J.E. and Walsh, S. Radiomics: The bridge between medical imaging and personalized medicine. Nat. Rev. Clin. On- col. 14:
22.Loessner D., Little J., Pettet G. and Hutmacher D. A multiscale road map of cancer spheroids: Incorporating experimental and mathematical modelling to understand cancer progression. J. Cel- lular Sci. 126:
23.Luján E., Guerra L., Soba A., Visacovsky N., Gandía D., Calvo J. and Suárez C. Mathematical modelling of microtumour infiltra- tion based on in vitro experiments. Int. Biol. 8:
24.Luján E., Soto D., Rosito M.S., Soba A., Guerra L., Calvo J.C., Marshall G. and Suárez C. Microenvironmental influence on mi- crotumour infiltration patterns:
25.Miller D. A tribute to Sidney Farber - the father of modern che- motherapy. Brit. J. Haemat. 134:
26.Motzer, R.J., Hutson, T.E., Tomczak, P., Michaelson, M.D., Bu- kowski, R.M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S.T., Chen, I., Bycott, P.W., Baum, C.M.and Figlin, R.A. Sunitinib versus interferon alfa in metastatic
27.
28.Park J. and Kim H. Radiomics as a quantitative imaging biomark- er: Practical considerations and the current standpoint in neuroon-
78 |
Gandía and Suárez |
||
|
cologic studies. Nuclear Med. Molec. Imag. 52: |
|
Mathematical modeling of human glioma growth based on brain |
29. |
Preziosi L. Cancer Modeling and Simulation; London, UK. |
|
topological structures: Study of two clinical cases. Plos One 7 (6): |
|
Chapman & HALL/CRC, 2003. |
|
e39616, 2012. |
30. |
Protopapa M., Zygogianni A., Stamatakos G., Antypas C., Armpil- |
34. |
Swanson K., Bridge C., Murray J. and Alvord E. Virtual and real |
|
ia C., Uzunoglu N. and Kouloulias V. Clinical implications of in |
|
brain tumors: Using mathematical modeling to quantify glioma |
|
silico mathematical modeling for glioblastoma: A critical review. J. |
|
growth and invasion. J. Neurol. Sci. 216: |
|
35. |
Tannock I. Treating the patient, not just the cancer. N. Eng. J. |
|
31. |
Savard M., Khan O., Hunt K. and Sunil V. Redrawing the lines: |
|
Med. 317: |
|
The next generation of treatment in metastatic breast cancer. |
36. |
Victori P. and Buffa F. The many faces of mathematical model- |
|
ASCO Educational Book |
|
ling in oncology. Brit. J. Radiol. 92 (1093): 20180856, 2019. |
32. |
Sim E., Yang I., |
37. |
Wang Z., Butner J., Kerketta R., Cristini V. and Deisboeck T. |
|
tinib for advanced |
|
Simulating cancer growth with multiscale |
|
Syst Rev – Intervention; Jan 16, 2018. |
|
Sem. Cancer Biol. 30: |
33. |
Suarez C., Maglietti F., Colonna M., Breitburd K. and Marshall G. |
|
|